Site Index - Pharmaceutical Executive

ADVERTISEMENT

FindPharma Custom Search
About Search
What's New

Deals
GSK Teams with Shenzhen Neptunus for Chinese Vaccines
GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people.
GSK Signs Deal with Concert Pharma to the Tune of $1 Billion
GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body.
GSK Grabs Derma Firm for $2.9 Billion
Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line.
Pfizer and Glaxo Join Forces in HIV Venture
The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market.
A Season in Financial Hell
From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal.
Gilead Buys CV Therapeutics (Update 1)
The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion.
Roche and Genentech Seal the Deal for $46.8 Billion
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.
Merck Takes Unusual Merger Tactic in Schering Deal
The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?
Astellas to Nominate Two Directors to CV Therapeutics Board
Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own.
 MORE ARTICLES

Discovery NewsWire
Lost in Translation: Perfectionist Protein-Maker Trashes Errors
Avian Flu Becoming More Resistant to Antiviral Drugs, Says University of Colorado at Boulder Study
To Climate-Change Worries, Add One More: Extended Mercury Threat
You Can't Clone My Jack Russell Terrier
Old Gastrointestinal Drug Slows Aging, McGill Researchers Say; Clioquinol Inhibits Action of the CLK1 Aging Gene, May Alleviate Alzheimer's
ADEAGies Foundation Announces Winners of William J. Gies Awards for Vision, Innovation, and Achievement; Awards to Be Presented at Celebration in Conjunction With 86th American Dental Education Association Annual Session
Most Babies With Uncomplicated Febrile Seizures Can Avoid Spinal Tap; Largest Review to Date Questions Current Recommendations
Obesity: Reviving the Promise of Leptin; The First Known Leptin-Sensitizing Agents Induce Mice to Lose Weight
Viagra's Other Talents: To Help a 'Signaling' Protein Shield the Heart From High Blood Pressure Damage
 MORE ARTICLES

Global Report
Understanding the New World Order of Emerging Markets
Pharma is wrestling to understand the emerging markets will be the engine of growth for future sales.
UK Group Recommends Path to Building Trust
A new report by the Royal College of Physicians breaks down the reasons why patients are disillusioned about access to medicines, and documents a steady growth in the lack of trust between industry and the NHS. More importantly, it gives recommendations on how to solve the problems.
Reforms Offer Good News for Trade
EC proposal loosens restrictions on drug packaging and information dissemination.
Animal Humanity
The new EU directive looks to reduce, refine, and eventually replace animal testing
Cash Flow Woes in EU
In Europe, it's different strokes for different folks at the top regulatory agencies
Open For Debate
Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems
Doing More With Less
In order to take a big step forward, GSK looks to employ smaller licensing deals and business units
Jumping the Gun
Britain's new approach to drug pricing isn't as bad as the industry feared.
Tightening the Chain
EU makes plans to police its supply chain
 MORE ARTICLES

India
India: An Emerging Knowledge Superpower
"India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub." For Dilip Shah, General Secretary of the Indian Pharmaceutical Alliance (IPA), India is currently on its way to undertake one of the greatest transformations ever experienced within the pharmaceutical industry, although the excitement has been over 30 years in the making.
 MORE ARTICLES

Marketing
Measuring the Value of KOL Interactions
Thought leaders are a critical component of a pharmaceutical company?s professional marketing and medical strategies. But companies face a real challenge in creating, maintaining, and leveraging those relationships while safely navigating logistical issues and regulatory waters.
UCB Teams with PatientsLikeMe to Learn What Patients Want
In an effort to learn as more about epilepsy sufferers, UCB will implement a social network that allows patients to communicate about their disease state and treatments. Think of it as one giant, online clinical trial.
Wyeth Winds Up With New Pristiq Campaign
What do you do when you are introducing a new drug in an already crowded category? Wyeth queried depression sufferers to find out what they want to see in a drug ad before launching its new DTC campaign for Pristiq.
On the Right Pathways
With staggering year-over-year growth, biosimilars are "the future of medicine." Marketers must position their companies for the inevitable changes.
Learning to Relate
A multi-phase implementation strategy can debunk the myth that social media won't work for pharma.
Amgen and CDC to Spearhead Anti-infection Campaign
Cancer patients worry not only about their disease, but also the side effects of the drugs they take to treat it. Now the Centers for Disease Control and Prevention and biologics firm Amgen are partnering on a multi-prong program to get patients to pay attention to another, related, danger: chemo-related infections.
New Bill to Curb Pharma ED Ads
Two Democratic Congressman have brewed up new legislation to target pharma erectile dysfunction ads rather than going after advertisements with sexually suggestive material in general. Industry experts don't think they have a chance, but the bill could still be a pain for fans of Viva Viagra.
Weathering the Storm
Marketers must stress that maintaining good health behaviors is one of the best things people can do to survive a down market.
Ad(Ventures) in Pharmaland
Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration.
 MORE ARTICLES

Meetings
The End of Quid Pro Quo
Exhibitor alert: Tchotchke entitlement is out, information immersion is in
Next Generation Event Consolidations
The path from chaos to compliance is consolidation
Introduction: Putting Your Best Face Forward
Meetings are the last area of unmanaged spend. In respose, Pharma is managing more and spending less
They Do Things Differently Over There: Meetings Management Without Borders
Meetings management programs applied globally can get lost in translation. But Pfizer, Lily, and GlaxoSmithKline are making theirs a success. Here's why.
Pharma Spoken Here
A boom is transforming Puerto Rico's meetings and conventions industry. What does it mean for pharma meeting planners?
How to Lose the E-Snooze
E-meetings may be cost-effective, but let's face it, they're often dull. Here are 8 ways to wake them up
Being Pharma Fluent
Pharma meetings aren't like other meetings. Executives and staff at KSL properties are trained to find out what makes them different and how to comply.
Creating a Buzz on the Convention Floor
Utilizing cutting-edge technologies can build an immersive brand experience for your next exhibit
Practical Tips for Mitigating Risk
Want to keep your medical education program on the straight and narrow? Consider peer review.
 MORE ARTICLES

PharmExec Direct
Pharma Trials Heading South
Diversity of ethnic groups and prevalence of Spanish language make Latin America an attractive destination for clinical trials.
No Such Thing as Free Drugs?
New medicines program may be a beacon of light for the newly jobless, but some wonder what issues might arise from such a ?good gesture.?
Wrangling Over Research Results
Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.
A Review of Tafas v. Doll
Appeals court paves the way for Patent and Trademark Office to adopt restrictive patent rules.
New Study Reveals Distribution Trends in Drug Sampling
Drug sampling is way up, but who is receiving the free medication? The American Journal of Public Health states that the majority of samples are distributed to the wealthy and insured. PhRMA, however, disagrees.
Data Mining Companies Score Legal Win in Maine
IMS Health, and a handful of other intelligence gathering companies, will be allowed to collect prescribing information from physicians in Maine. This is a big win for pharma companies that purchase reports from data mining companies to better market to doctors. The last hurdle is Vermont, which still has an outstanding lawsuit against the firms.
BioMS Medical Signs $500 Million Agreement with Lilly
Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS.
Preemption Gets Boost from Bush
State and federal governments do battle over who is responsible for faulty or mislabeled drugs and devices, while patients, pharma manufacturers, and Medtronic wait for answers. Is federal preemption the answer?
BMS Cuts Bloated Manufacturing Arm to Bolster R&D
Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing.
 MORE ARTICLES

PharmExec Direct Marketing Edition
GSK Chooses MediaCom for a Billion-Dollar Planner Contract
GlaxoSmithKline locks up MediaCom as its only ad-buying/planning provider. The agency will handle GSK's massive ad spend, which last year hovered around $1.1 billion.
Vertex Pharmaceuticals Brings Transparency Online
Drug manufacturer shakes things up with new Web site that functions as an open book into the world of Vertex Pharmaceuticals. The company hopes that its transparent approach to design will be a lesson to pharma companies still fearful of online media.
Arkansas Attorney General Takes J&J to Task
The State of Arkansas filed suit against Risperdal manufacturer Johnson & Johnson, claiming promotion of the drug for nonmedical uses has led to increased prescriptions being written and bigger payouts by Medicaid.
In Defense of Peer Review: Waxman Opponents Argue for Distribution of Off-Label Info
Peer-review advocates speak out against Congressman Waxman?s stance on a new policy that would allow pharma to distribute unbiased journal articles to doctors without prior approval.
Doc-Driven Search Site Lists Top Search Terms
A physician-oriented search engine reveals its most-searched terms. Among the winners: breast and lung cancer, cortisol, and HbA1c/glycated hemoglobin. Nowhere to be seen: pharmaceutical products.
Discovery Health Documentary Spotlights Diabetes and Offers a CME Credit
A new pharma-sponsored documentary chronicles one doctor?s adventure around the world as she searches for stories about living with diabetes. The program, sponsored by Novo Nordisk, enlightens viewers and offers physicians a chance to earn one AMA-approved CME credit.
GSK Told to Update Avandia Warnings
Faced with contradictory data about the safety of the diabetes treatment, FDA asks for a black-box warning and additional trials. But how much damage will the black box do?
Lilly's New Blood Thinner No Blockbuster
Safety Risks, Generic Threat Scale Down Big Hopes
Stormy Forecast for Pharma in 2008
Bright Spots Are Emerging Markets, Specialty Drugs, Says IMS Health
 MORE ARTICLES

R&D
ASCO Roundup: Winners, Losers, and Also Rans
Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida.
How Evidence Based Medicine is Impacting Global Clinical and Reimbursement Practices
Evidence-based medicine is fast becoming one of the key concepts in clinical and reimbursement practices in the developed world
Pfizer Pulls Two Late-stage Drugs from Development
A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them.
Transforming Clinicians into Industry Leaders
Could physician behavior have a positive impact on Drug Development?
Vaccines for All
The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
Latest Flu Season Sets Tamiflu Back but Doesn't Knock It Down
The Tamiflu-resistant flu strain means increased sales for GSK's Relenza, but doesn't mean the end for the number-one antiviral.
Pfizer Sheds More Staff
Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good?
Insuring Global Clinical Trials
As global regulators set up rules for liability insurance for clinical trials, the playing field has grown complex for sponsors. This article reviews the key issues and offers a look at how European, Asian, and Latin American countries handle clinical trial insurance.
Merck Submits Request to Market Gardasil to Men
Merck isn't bragging about the positive data it received regarding the use of its landmark HPV vaccine in men. But the pharma giant also isn't wasting time submitting the info to FDA. Pharm Exec talked to the lead investigator behind the trials to find out why this could be another milestone for Merck.
 MORE ARTICLES

Sales
Managing the Crisis of Marginalization
The key to managing the pharma sales force is to know when the customer wants good customer service, and when the customer needs good self-service.
Rx Scripts Spike in Wake of Swine Flu
New prescriptions for antiviral treatments get huge boost due to H1N1 epidemic. Numbers exceed those seen during this year's influenza season, and the numbers are climbing.
Higher Learning for Pharma Sales Reps
American Society of Hypertension to launch new education program that grants sales reps hypertension accreditation after rigorous training.
US Pharma Market To Decline in 2009
IMS has revised its 2009, forecast and the outlook isn't pretty for the United States, which looks to drop 1 to 2 percent in the coming year.
Goodbye, Willy Loman
The days of pharma sales reps going office-to-office with samples and brochures are done. These days, they need to turn their attention to payers, pharmacists, and consumers
Make a Match
Big Pharma is finally making a commitment to partner-based outsourcing.
Drug Sales See Minimal Climb in 2008
Farewell to double-digit growth. Between patent expirations and a sagging economy, sales of prescription drugs grew only 1.3 percent last year.
The New Sales Force
The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with—and how it's working
Physicians Continue to Limit Face Time with Reps
SK&A released grim news last week - nearly two-thirds of sales reps are either banned or forced to make an appointment before they can set foot in a doctor?s office.
 MORE ARTICLES

Strategy
Oscient Pharmaceuticals Lays Off 180 Reps
Oscient trims 180 sales, marketing, and corporate jobs in the wake of patent expirations, generic competition.
Emerging Leaders 2009: The Faces of Innovation
Our second annual Emerging Leadership Awards cast the spotlight on 27 young rising stars most notable for their dedication and contribution to the pharma industry. Here's a closer look at why.
Stealth Pharmas
The third annual audit reveals how pharma's "other half" performs.
Pay For Play
The P4P movement is here. Pharma marketers, it's time to take note.
Amylin Drops 200 Sales Reps
As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.
Bio Companies Low on Venture Capital Cash
As the economy continues to retract, fewer biotech companies are finding the funding they need to survive, driving more firms to sell or close shop.
Reading the "Risk Radar"
Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.
Cancer Quagmire
Clear dialogue between manufacturers and payers will be essential to the process of transforming oral oncologic's dynamics.
The Shakeout
When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.
 MORE ARTICLES

Technology
Calculating Risk
A risk-based approach to records and information management can be an integral part of the effort to reduce costs stemming from litigation.
Bank on IT
Tough economic tmes call for a bold approach to evolving information technology solutions.
Search for: Meaning
Here's how to search for meaning through unstructured data.
Ortho-McNeil Talks ADHD On Facebook
The Johnson & Johnson subsidiary launched an unbranded support group page on social networking site Facebook giving moms of kids with ADHD a place to learn, but not a place to converse.
J&J Goes From Boob Tube to YouTube
Johnson & Johnson launched its healthcare video channel on Google?s YouTube, signaling pharma?s further entrenchment into the online community
Genzyme Launches Digital Assault on Counterfeiters
Rather than wait to see which ePedigree legislation becomes law, biotech firm Genzyme has taken the initiative and implemented an electronic track-and-trace program to clamp down on fake meds.
Researchers to Share Ideas in Virtual Park
The Hershey Center for Applied Research is bringing social networking to researchers and academics with a new platform that could become a Facebook for the life science community. Does the site, dubbed KnowledgeMesh, have what it takes cut through the Web 2.0 clutter? Pharm Exec takes a closer look.
Sermo Joins With Med Mags
Still hoping the journal article on your drug's adverse reactions will go unnoticed? Think again. A new partnership between medical journals and physician social networking site Sermo just made chatting about drugs a lot easier.
Want to Be in a Health Plan? Think Like One
Pharmacoactuarial analysis helps drug companies communicate value to health plans
 MORE ARTICLES

ADVERTISEMENT

Click here